[BIO USA 2025] Prestige Biopharma Booth HighlightsPrestige Biopharma is participating in BIO USA 2025, held in Boston this June.As a leading CDMO specializing in antibody therapeutics,we are expanding our global partnerships through cutting-edge GMP facilities and comprehensive end-to-end services.Take a glimpse into our booth and experience the event atmosphere through this short video.📍 Booth No. 2853 | 📅 June 3–6, 2025

Go to the promotional videoWe're at BIO USA 2025! From discovery to delivery — driving innovation in antibody therapeutics and biomanufacturing. Meet Prestige Biopharma Group at the heart of global biotech conversations. 📍 Booth No. 2853 ✔️ Antibody Therapeutics ✔️ State-of-the-Art GMP Facilities ✔️ End-to-End CDMO Services Stay tuned for more updates from Boston!  #BIOUSA #CDMO #Biopharma #PrestigeBiopharma 

The first international symposium of Prestige Biopharma IDC was a meaningful event that shared advanced biopharmaceutical technologies and platform development achievements while discussing the possibilities of collaboration and innovation.On the first day, presentations covered topics such as disease modulation, new drug development strategies, and immune-modulating virus therapies, offering insights into the future of advanced biotechnologies.On the second day, discussions focused on global biopharma collaboration and innovation cases, strategies for supporting biotech startups, and R&D cooperation achievements, with panel discussions presenting growth directions and collaboration strategies for the biopharma industry.This symposium served as an opportunity to foster networking and information exchange among experts, solidifying Prestige Biopharma IDC's vision to become a global innovation hub in the biopharma industry.

Prestige Biopharma Group has taken its first step toward becoming a global innovation hub in the biopharma industry with the opening ceremony of its R&D control tower, the Innovation Drug Center (IDC).With its cutting-edge research platform and global network, IDC is dedicated to the development of antibody therapeutics and biosimilars for the treatment of intractable diseases, embodying the vision of "Innovation for Life."The international symposium held alongside the opening ceremony provided an opportunity to share achievements in biopharmaceutical technologies and platform development, while exploring the possibilities of collaboration and innovation.Moving forward, IDC aims to lead the global biopharma industry and establish itself as a world-class biopharma cluster.We kindly ask for your continued interest and support in the journey of the Innovation Drug Center.

http://pbpidc.com/index.php/registration/

- Following approval by the European Commission, Prestige Biopharma's Herceptin biosimilar would become the first biosimilar from a Singaporean company to be authorized in the European Union.Singapore, July 26, 2024 — Prestige Biopharma, a pioneer in biopharmaceuticals, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended marketing authorization for Tuznue®, a Herceptin (trastuzumab) biosimilar. This milestone positions Prestige Biopharma to become the first Singaporean firm to commercialize its biosimilar in the European Union.The CHMP’s positive opinion is based on clinical evidence from Phase 1 and Phase 3 clinical studies that tested the biosimilarity of Tuznue® to Herceptin®. The Phase 1 clinical PK study in healthy volunteers demonstrated PK equivalence, as well as similarity in safety and immunogenicity. Finally, the global Phase 3 confirmatory efficacy and similarity study met its primary endpoint and demonstrated similarity in efficacy, PK, safety, and immunogenicity in HER2-positive patients with early breast cancer. This favourable decision is a crucial step toward final approval from the European Commission (EC). Once approved, Tuznue® will be commercialized across Europe.Prestige Biopharma has already established licensing agreements with major pharmaceutical partners such as Dr. Reddy’s, Tabuk, Cipla, and Pharmapark for global marketing and sales. These agreements are set to generate immediate milestone payments and provide early revenue for the company. Negotiations are also underway to ensure a strong market entry for Tuznue® in Europe."Receiving a positive CHMP opinion for Tuznue® marks a major milestone for Prestige Biopharma, significantly advancing our revenue generation strategy and accelerating future pipeline approvals,” said Lisa Park, the CEO of Prestige Biopharma. “This recognition solidifies our position as a leading biosimilar developer. We are committed to leveraging this achievement to enhance our market presence and drive continued success."About TUZNUE® (HD201, biosimilar trastuzumab)Tuznue® is a biosimilar of Herceptin® (trastuzumab), developed to offer a more cost-effective therapeutic alternative for patients. It maintains comparable efficacy and safety profiles to the original branded medication. Tuznue® is indicated for the treatment of patients with HER2-positive metastatic breast cancer (MBC), HER2-positive early breast cancer (EBC), and HER2-positive metastatic gastric cancer (MGC).About Prestige Biopharma:Established in 2015 in Singapore, Prestige Biopharma is a biopharmaceutical company with a diversified portfolio. Among its many pipelines, a first-in-class antibody drug and key biosimilars referencing blockbuster drugs are ongoing clinical development. Notably, the first-in-class, PAUF-based antibody drug, ulenistamab, has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Ministry of Food and Drug Safety (MFDS) in Korea, as well as Fast Track Designation by the U.S. FDA. A global Phase 1/2a clinical trial is currently underway in the United States, Europe, and Asia, with the aim of bringing this innovative therapy to the clinic. Prestige Biopharma is also part of the Cancer Moonshot initiatives in pursuit of accelerating scientific discovery and innovation.